

and wherein each of said C₁₋₂-alkyl-, C₁₋₂-alkyl-O-, C₁₋₂-alkyl-CO-, cyclopropyl- or cyclopropyl-O- substituents may be substituted with 1 or more substituents independently selected from the group of fluoro, -CF₃, -CHF₂, -CH₂F and -CN;

5 **R**² is hydrogen;

R³ is selected from the group of ~~R-1,1,1-trifluoro-2-ethoxy~~ and ~~S-1,1,1-trifluoro-2-ethoxy~~
(S)-2,2,2-trifluoro-1-methyl-ethoxy and (R)-2,2,2-trifluoro-1-methyl-ethoxy;

R⁴ is hydrogen;


R⁵ is hydrogen;







10 **R**⁶ is selected from the group of C₁₋₄-alkyl-SO₂- and -CN;







R⁷ is hydrogen.







7. ~~A compound according to claim 1 selected from the group of~~







15


















































the diastereomer of each of the above listed compounds with R-configuration at R^1 and R-configuration at R^3 ;

the diastereomer of each of the above listed compounds with S-configuration at R^1 and S-configuration at R^3 ;



- 5 the diastereomer of each of the above listed compounds with R-configuration at R^1 and S-configuration at R^3 ;







the diastereomer of each of the above listed compounds with S-configuration at R^1 and R-configuration at R^3 ;







and a mixture of diastereomers thereof.







10







7. A compound according to claim 1, of the formula
















































or



wherein said compound is selected from the group consisting of:

the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3;

the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3;

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

wherein, in each such stereoisomer, the chiral carbon atom designated by the numeral 2 is always in the syn configuration with respect to the chiral carbon atom designated by the numeral 1;

or a mixture of two or more of the foregoing stereoisomer.

8. A compound according to any of claims 1, 2, 3, 4, 5 or 6, wherein the absolute configuration at **R**¹ is R.

9. A compound according to any of claims 1, 2, 3, 4, 5 or 6, wherein the absolute configuration at **R**¹ is S.

10. A compound according to any of claims 1, 2, 3, 4, 5, 6, 7, 8 or 9, wherein the compounds is in the form of a salt.

~~11. A compound according to any of claims 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, wherein the compound is in the form of a solvate.~~

- 5 ~~12~~11. A compound according to any one of claims 1 to ~~11~~10 for use in or for use as a medicament, wherein the use of the medicament or the medicament is for a therapeutic or prophylactic method

~~(a) for the treatment of a CNS disease, the treatment of which is accessible by the inhibition of GlyT1,~~

~~(b) for the treatment of a disease that is accessible by the inhibition of GlyT1,~~

5 (ea) for the treatment, amelioration or prevention of a condition selected from the group consisting of positive and negative symptoms of schizophrenia, psychoses and cognitive impairments associated with schizophrenia, Alzheimer's Disease, prodromal Alzheimer's disease, amnestic mild cognitive impairment and psychiatric disorders;

(eb) for the treatment of Alzheimer's disease, prodromal Alzheimer's disease, amnestic mild cognitive impairment or cognitive impairment associated with Alzheimer's disease,
10 ease,

(ec) for the treatment of schizophrenia or cognitive impairment associated with schizophrenia,

(fd) for the treatment of psychoses.

15 ~~13~~12. Pharmaceutical composition or medicament comprising a compound according to any one of claims 1 to ~~11~~10.

~~14. Use of a compound according to any one of claims 1 to 11 for the manufacture of a medicament as defined in claim 12.~~

20

~~15~~13. Combination of a compound according to any one of claims 1 to ~~11~~10 with another active agent, that


(a) is useful for the therapeutic treatment of a disease or condition as defined in claim ~~12~~11 under (a) or (b) or (c) or (d) ~~or (e) or (f)~~ or

25 (b) is useful for the prophylactic treatment of a condition or disease as defined in claim ~~12~~11 under (a) or (b) or (c) or (d) ~~or (e) or (f)~~ or


(c) is useful for the manufacture of a medicament for the treatment of a condition or disease as defined in claim ~~12~~11 under (a) or (b) or (c) or (d) ~~or (e) or (f)~~.

30


1614. A compound of general formula (II), (III), (IV), (V) or (VI):




general formula (II)




general formula (III)



general formula (IV)



general formula (V)



general formula (VI)

wherein in each of those independent formulas

R^1 , R^2 , R^4 , R^5 , R^6 , and R^7 have the meaning as in any of claims 1 to 9,

R^2 in general formula (II) to (V) is selected from the group consisting of C₁₋₄-alkyl-, C₁₋₄-alkyl-O-, -CN and C₃₋₆-cycloalkyl-,

R^2 in general formula (VI) is selected from the group consisting of hydrogen, C₁₋₄-alkyl-, C₁₋₄-alkyl-O-, -CN and C₃₋₆-cycloalkyl-,

wherein each of said C₁₋₄-alkyl-, C₁₋₄-alkyl-O- and C₃₋₆-cycloalkyl-group may be optionally substituted with 1, 2, 3 or more substituents independently selected from the group of fluoro, -CF₃, -CHF₂, -CH₂F and -CN;


R^8 is C₁₋₄ alkyl-O-, optionally substituted by 1 or more substituents independently selected from each other from the group of fluoro, chloro, bromo, -CN, C₁₋₄ alkyl-O-, C₁₋₄

alkyl-, phenyl and benzyl, wherein phenyl and benzyl optionally may be substituted with one or more substituents independently selected from each other from the group of fluoro, chloro, bromo, -CN, C₁₋₄ alkyl-O-, C₁₋₄ alkyl-; and

- 5 PG is a protecting group for an amino function selected from the group consisting of tert-butoxycarbonyl-, 9-fluorenylmethoxycarbonyl-, benzyl-, and 2,4-dimethoxybenzyl-.

17. ~~Use of a compound according to any one or more of claims 1 to 11 in the manufacture of a medicament for the treatment of a disease or condition selected from the group consisting of (a) a CNS disease, the treatment of which is accessible by the inhibition of GlyT1, (b) a disease that is accessible by the inhibition of GlyT1, (c) a condition selected from the group consisting of positive and negative symptoms of schizophrenia, psychoses and cognitive impairments associated with schizophrenia, Alzheimer's Disease, and psychiatric disorders, (d) Alzheimer's disease or cognitive impairment associated with Alzheimer's disease, (e) schizophrenia or cognitive impairment associated with schizophrenia, and (f) psychoses.~~

15. A compound according to claim 1, of the formula



20 wherein said compound is selected from the group consisting of:

the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3;


the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3; and

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

wherein, in each such stereoisomer, the chiral carbon atom designated by the numeral 2 is always in the syn configuration with respect to the chiral carbon atom designated by the numeral 1;

or a mixture of two or more of the foregoing stereoisomers.


16. A compound according to claim 1, of the formula



with R-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration
with respect to the chiral carbon atom designated by the numeral 1.


17. A compound according to claim 1, of the formula



with S-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration
with respect to the chiral carbon atom designated by the numeral 1.

18. A compound according to claim 1, of the formula




with R-configuration at the chiral carbon atom designated by the numeral 1;

5

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.

10

19. A compound according to claim 1, of the formula




with S-configuration at the chiral carbon atom designated by the numeral 1;

15

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.

20. A compound according to claim 1, of the formula



wherein said compound is selected from the group consisting of:

the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3;


the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3; and

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

wherein, in each such stereoisomer, the chiral carbon atom designated by the numeral 2 is always in the syn configuration with respect to the chiral carbon atom designated by the numeral 1;

or a mixture of two or more of the foregoing stereoisomers.

21. A compound according to claim 1, of the formula




5 with R-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration
with respect to the chiral carbon atom designated by the numeral 1.

10


22. A compound according to claim 1, of the formula



with S-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.


5 23. A compound according to claim 1, of the formula



with R-configuration at the chiral carbon atom designated by the numeral 1;

10 wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.


24. A compound according to claim 1, of the formula



15 with S-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.

25. A compound according to claim 1, of the formula



wherein said compound is selected from the group consisting of:

the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3;


the diastereomer with R-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3; and

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

wherein, in each such stereoisomer, the chiral carbon atom designated by the numeral 2 is always in the syn configuration with respect to the chiral carbon atom designated by the numeral 1;

5 or a mixture of two or more of the foregoing stereoisomers.

26. A compound according to claim 1, of the formula




with R-configuration at the chiral carbon atom designated by the numeral 1;

10

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.

27. A compound according to claim 1, of the formula




15

with S-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.

5

28. A compound according to claim 1, of the formula




with R-configuration at the chiral carbon atom designated by the numeral 1;

10

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.

29. A compound according to claim 1, of the formula




15

with S-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.

30. A compound according to claim 1, of the formula



wherein said compound is selected from the group consisting of:

the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3;

the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3; and


the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

wherein, in each such stereoisomer, the chiral carbon atom designated by the numeral 2 is always in the syn configuration with respect to the chiral carbon atom designated by the numeral 1;

5

or a mixture of two or more of the foregoing stereoisomers.


31. A compound according to claim 1, of the formula



10 with R-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.

15 32. A compound according to claim 1, of the formula




with S-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration
with respect to the chiral carbon atom designated by the numeral 1.

5

33. A compound according to claim 1, of the formula




with R-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration
with respect to the chiral carbon atom designated by the numeral 1.

10


34. A compound according to claim 1, of the formula



with S-configuration at the chiral carbon atom designated by the numeral 1;

5 wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.

35. A compound according to claim 1, of the formula



10 wherein said compound is selected from the group consisting of:

the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

15

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3;


the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3; and

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

wherein, in each such stereoisomer, the chiral carbon atom designated by the numeral 2 is always in the syn configuration with respect to the chiral carbon atom designated by the numeral 1;

or a mixture of two or more of the foregoing stereoisomers.


36. A compound according to claim 1, of the formula



with R-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.


37. A compound according to claim 1, of the formula



with S-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.


38. A compound according to claim 1, of the formula



with R-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.


39. A compound according to claim 1, of the formula



with S-configuration at the chiral carbon atom designated by the numeral 1;

- 5 wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.

40. A compound according to claim 1, of the formula



- 10 wherein said compound is selected from the group consisting of:

the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3;


the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3; and

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

wherein, in each such stereoisomer, the chiral carbon atom designated by the numeral 2 is always in the syn configuration with respect to the chiral carbon atom designated by the numeral 1;

or a mixture of two or more of the foregoing stereoisomers.


41. A compound according to claim 1, of the formula



with R-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.


42. A compound according to claim 1, of the formula



with S-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.


43. A compound according to claim 1, of the formula



with R-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.


44. A compound according to claim 1, of the formula



with S-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration with respect to the chiral carbon atom designated by the numeral 1.

45. A compound according to claim 1, of the formula



wherein said compound is selected from the group consisting of:

the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3;


the stereoisomer with R-configuration at the chiral carbon atom designated by the numeral 1 and S-configuration at the chiral carbon atom designated by the numeral 3; and

the stereoisomer with S-configuration at the chiral carbon atom designated by the numeral 1 and R-configuration at the chiral carbon atom designated by the numeral 3;

wherein, in each such stereoisomer, the chiral carbon atom designated by the numeral 2 is always in the syn configuration with respect to the chiral carbon atom designated by the numeral 1;

or a mixture of two or more of the foregoing stereoisomers.

46. A compound according to claim 1, of the formula




with R-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration
with respect to the chiral carbon atom designated by the numeral 1.

5

47. A compound according to claim 1, of the formula




with S-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration
with respect to the chiral carbon atom designated by the numeral 1.

10


48. A compound according to claim 1, of the formula



with R-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration
with respect to the chiral carbon atom designated by the numeral 1.

49. A compound according to claim 1, of the formula



with S-configuration at the chiral carbon atom designated by the numeral 1;

wherein the chiral carbon atom designated by the numeral 2 is in the syn configuration
with respect to the chiral carbon atom designated by the numeral 1.